<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pateras,I.S.</style></author><author><style face="normal" font="default" size="100%">Williams, C.</style></author><author><style face="normal" font="default" size="100%">Gianniou, D. D.</style></author><author><style face="normal" font="default" size="100%">Margetis, A. T.</style></author><author><style face="normal" font="default" size="100%">Avgeris, M.</style></author><author><style face="normal" font="default" size="100%">Rousakis, P.</style></author><author><style face="normal" font="default" size="100%">Legaki, A. I.</style></author><author><style face="normal" font="default" size="100%">Mirtschink, P.</style></author><author><style face="normal" font="default" size="100%">Zhang, W.</style></author><author><style face="normal" font="default" size="100%">Panoutsopoulou, K.</style></author><author><style face="normal" font="default" size="100%">Delis, A. D.</style></author><author><style face="normal" font="default" size="100%">Pagakis, S. N.</style></author><author><style face="normal" font="default" size="100%">Tang, W.</style></author><author><style face="normal" font="default" size="100%">Ambs, S.</style></author><author><style face="normal" font="default" size="100%">Warpman Berglund, U.</style></author><author><style face="normal" font="default" size="100%">Helleday, T.</style></author><author><style face="normal" font="default" size="100%">Varvarigou, A.</style></author><author><style face="normal" font="default" size="100%">Chatzigeorgiou, A</style></author><author><style face="normal" font="default" size="100%">Nordstrom, A.</style></author><author><style face="normal" font="default" size="100%">Tsitsilonis, O.E.</style></author><author><style face="normal" font="default" size="100%">Trougakos, I.P.</style></author><author><style face="normal" font="default" size="100%">Gilthorpe, J. D.</style></author><author><style face="normal" font="default" size="100%">Frisan, T.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Short term starvation potentiates the efficacy of chemotherapy in triple negative breast cancer via metabolic reprogramming</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Translational Medicine</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Drug-Related Side Effects and Adverse Reactions</style></keyword><keyword><style  face="normal" font="default" size="100%">*Triple Negative Breast Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">breast cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Caloric Restriction</style></keyword><keyword><style  face="normal" font="default" size="100%">Diet, Reducing</style></keyword><keyword><style  face="normal" font="default" size="100%">Fasting</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Metabolic reprogramming</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Mitochondria</style></keyword><keyword><style  face="normal" font="default" size="100%">Obesity</style></keyword><keyword><style  face="normal" font="default" size="100%">Oncological treatment</style></keyword><keyword><style  face="normal" font="default" size="100%">Oxidative Stress</style></keyword><keyword><style  face="normal" font="default" size="100%">Reactive Oxygen Species</style></keyword><keyword><style  face="normal" font="default" size="100%">Starvation</style></keyword><keyword><style  face="normal" font="default" size="100%">Triple negative breast cancer</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Mar 3</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">21</style></volume><pages><style face="normal" font="default" size="100%">169</style></pages><isbn><style face="normal" font="default" size="100%">1479-5876 (Electronic)1479-5876 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: Chemotherapy (CT) is central to the treatment of triple negative breast cancer (TNBC), but drug toxicity and resistance place strong restrictions on treatment regimes. Fasting sensitizes cancer cells to a range of chemotherapeutic agents and also ameliorates CT-associated adverse effects. However, the molecular mechanism(s) by which fasting, or short-term starvation (STS), improves the efficacy of CT is poorly characterized. METHODS: The differential responses of breast cancer or near normal cell lines to combined STS and CT were assessed by cellular viability and integrity assays (Hoechst and PI staining, MTT or H(2)DCFDA staining, immunofluorescence), metabolic profiling (Seahorse analysis, metabolomics), gene expression (quantitative real-time PCR) and iRNA-mediated silencing. The clinical significance of the in vitro data was evaluated by bioinformatical integration of transcriptomic data from patient data bases: The Cancer Genome Atlas (TCGA), European Genome-phenome Archive (EGA), Gene Expression Omnibus (GEO) and a TNBC cohort. We further examined the translatability of our findings in vivo by establishing a murine syngeneic orthotopic mammary tumor-bearing model. RESULTS: We provide mechanistic insights into how preconditioning with STS enhances the susceptibility of breast cancer cells to CT. We showed that combined STS and CT enhanced cell death and increased reactive oxygen species (ROS) levels, in association with higher levels of DNA damage and decreased mRNA levels for the NRF2 targets genes NQO1 and TXNRD1 in TNBC cells compared to near normal cells. ROS enhancement was associated with compromised mitochondrial respiration and changes in the metabolic profile, which have a significant clinical prognostic and predictive value. Furthermore, we validate the safety and efficacy of combined periodic hypocaloric diet and CT in a TNBC mouse model. CONCLUSIONS: Our in vitro, in vivo and clinical findings provide a robust rationale for clinical trials on the therapeutic benefit of short-term caloric restriction as an adjuvant to CT in triple breast cancer treatment.</style></abstract><accession-num><style face="normal" font="default" size="100%">36869333</style></accession-num><notes><style face="normal" font="default" size="100%">Pateras, Ioannis SWilliams, ChloeGianniou, Despoina DMargetis, Aggelos TAvgeris, MargaritisRousakis, PantelisLegaki, Aigli-IoannaMirtschink, PeterZhang, WeiPanoutsopoulou, KonstantinaDelis, Anastasios DPagakis, Stamatis NTang, WeiAmbs, StefanWarpman Berglund, UlrikaHelleday, ThomasVarvarigou, AnastasiaChatzigeorgiou, AntoniosNordstrom, AndersTsitsilonis, Ourania ETrougakos, Ioannis PGilthorpe, Jonathan DFrisan, TeresaengResearch Support, Non-U.S. Gov'tEngland2023/03/04 06:00J Transl Med. 2023 Mar 3;21(1):169. doi: 10.1186/s12967-023-03935-9.</style></notes><custom2><style face="normal" font="default" size="100%">PMC9983166</style></custom2><auth-address><style face="normal" font="default" size="100%">2nd Department of Pathology, &quot;Attikon&quot; University Hospital, Medical School, National and Kapodistrian University of Athens, 124 62, Athens, Greece. ipateras@med.uoa.gr.Department of Integrative Medical Biology, Umea University, 901 87, Umea, Sweden.Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 157 84, Athens, Greece.2nd Department of Internal Medicine, Athens Naval and Veterans Hospital, 115 21, Athens, Greece.Laboratory of Clinical Biochemistry-Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, &quot;P. &amp; A. Kyriakou&quot; Children's Hospital, 115 27, Athens, Greece.Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, 157 71, Athens, Greece.Department of Biology, School of Science, National and Kapodistrian University of Athens, 157 84, Athens, Greece.Department of Physiology, Medical School, National and Kapodistrian University of Athens, 115 27, Athens, Greece.Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine, Technische Universitat Dresden, 013 07, Dresden, Germany.Swedish Metabolomics Centre, Department of Plant Physiology, Umea University, 901 87, Umea, Sweden.Centre for Basic Research, Bioimaging Unit, Biomedical Research Foundation, Academy of Athens, 115 27, Athens, Greece.Molecular Epidemiology Section, Laboratory of Human Carcinogenesis, Center for Cancer Research (CCR), NCI, NIH, Bethesda, MD, 20892-4258, USA.Data Science &amp; Artificial Intelligence, R&amp;D, AstraZeneca, Gaithersburg, MD, USA.Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, 171 76, Stockholm, Sweden.Weston Park Cancer Centre, Department of Oncology and Metabolism, University of Sheffield, Sheffield, S10 2RX, UK.Department of Paediatrics, University of Patras Medical School, General University Hospital, 265 04, Patras, Greece.Department of Molecular Biology and Umea Centre for Microbial Research (UCMR), Umea University, 901 87, Umea, Sweden. teresa.frisan@umu.se.</style></auth-address></record></records></xml>